Unleash Immuno Oncolytics

Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells.